Allianz Asset Management GmbH Boosts Position in The Clorox Company $CLX

Allianz Asset Management GmbH boosted its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 510.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 140,449 shares of the company's stock after acquiring an additional 117,442 shares during the quarter. Allianz Asset Management GmbH owned 0.11% of Clorox worth $16,864,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CLX. Wealth Enhancement Advisory Services LLC increased its position in Clorox by 17.9% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 57,934 shares of the company's stock valued at $8,531,000 after acquiring an additional 8,793 shares during the last quarter. QRG Capital Management Inc. increased its position in Clorox by 10.0% during the first quarter. QRG Capital Management Inc. now owns 2,492 shares of the company's stock valued at $367,000 after acquiring an additional 226 shares during the last quarter. State of Alaska Department of Revenue increased its position in Clorox by 2.2% during the first quarter. State of Alaska Department of Revenue now owns 14,430 shares of the company's stock valued at $2,124,000 after acquiring an additional 315 shares during the last quarter. PFG Investments LLC increased its position in Clorox by 13.2% during the first quarter. PFG Investments LLC now owns 4,154 shares of the company's stock valued at $612,000 after acquiring an additional 485 shares during the last quarter. Finally, Stonegate Investment Group LLC increased its position in Clorox by 52.7% during the first quarter. Stonegate Investment Group LLC now owns 2,070 shares of the company's stock valued at $305,000 after acquiring an additional 714 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Insider Buying and Selling

In related news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer directly owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.63% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on CLX. Citigroup reduced their price target on Clorox from $135.00 to $130.00 and set a "neutral" rating for the company in a research report on Wednesday, October 8th. Wells Fargo & Company reduced their price target on Clorox from $130.00 to $125.00 and set an "equal weight" rating for the company in a research report on Thursday, September 25th. Deutsche Bank Aktiengesellschaft reduced their price target on Clorox from $135.00 to $128.00 and set a "hold" rating for the company in a research report on Monday, October 13th. UBS Group reduced their price target on Clorox from $134.00 to $128.00 and set a "neutral" rating for the company in a research report on Wednesday, October 8th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Clorox in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat.com, Clorox presently has an average rating of "Reduce" and a consensus target price of $130.20.

Clorox Stock Performance

NYSE:CLX opened at $119.60 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The Clorox Company has a 12-month low of $116.53 and a 12-month high of $171.37. The stock has a 50-day moving average price of $121.56 and a 200 day moving average price of $127.42. The stock has a market capitalization of $14.56 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.99 and a beta of 0.52.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm had revenue of $1.99 billion during the quarter, compared to analysts' expectations of $1.94 billion. During the same quarter last year, the business posted $1.82 earnings per share. The firm's revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 dividend on an annualized basis and a yield of 4.1%. Clorox's dividend payout ratio is presently 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.